real peptides FAQ

Discard the vial and request a replacement if temperature data logging confirms exposure above 8°C for more than 2 hours. Lyophilized peptides tolerate brief ambient temperature exposure (less than 24 hours at 20–25°C), but once reconstituted, the tripeptide structure degrades rapidly at elevated temperatures. The degradation is invisible—the solution won't change color or clarity, but the biological activity will be lost. Temperature excursions are the single most common cause of

Refrigerate it immediately and use it within 7 days rather than the standard 14–28-day timeline. Melatonin degradation doubles for every 10°C above 4°C, so 8–12 hours at 22°C causes the same oxidative loss as 3–4 days under refrigeration. The solution is not ruined. MT1/MT2 receptor binding assays tolerate 10–15% potency loss without statistical impact. But you've consumed a significant portion of the stability budget. Do not leave reconstituted melatonin at room temperature again; even brief thermal excursions accumulate and shorten usable research timelines.

Reduce your dose to 0.3–0.5mg and take it 90 minutes before bed instead of 30 minutes before. Next-day grogginess indicates residual receptor occupancy or extended plasma clearance time, both of which scale with dose. Doses above 3mg saturate MT1/MT2 receptors without increasing sleep efficacy, only extending the duration of receptor binding. Alternatively, switch to sublingual administration, which produces faster onset and shorter duration, clearing plasma more completely by morning. If grogginess persists at low doses, assess CYP1A2 activity. Slow metabolizers clear melatonin more slowly and may need even lower doses or alternative circadian interventions.

Extend treatment to eight weeks before concluding non-response, but verify two factors first: subcutaneous injection technique and underlying neuropathy subtype. Intradermal injection (too shallow) produces local irritation and poor systemic absorption. Confirm injection depth is 4–6 mm using proper pinch technique. Second, review whether your small fiber neuropathy has confirmed inflammatory features: patients with purely metabolic or idiopathic small fiber neuropathy show slower and less consistent response than those with sarcoidosis or other immune-mediated etiologies. If pain persists at eight weeks despite verified technique and appropriate subtype, consider corneal confocal microscopy or repeat skin biopsy at 12 weeks to assess whether structural nerve improvement is occurring despite ongoing symptoms. Regeneration sometimes precedes pain resolution.

The package is likely still viable if it was shipped with 72-hour thermal packaging and dispatched early in the week. Check the carrier tracking for total transit time. If the package spent fewer than 72 hours from dispatch to delivery, properly rated thermal packaging should have maintained cold chain integrity even through weekend facility delays. If transit exceeded 72 hours, refrigerate the peptide immediately upon receipt and contact the supplier to discuss replacement or thermal validation testing. At Real Peptides, we avoid weekend delay risk entirely by restricting SS-31 shipping to Monday–Wednesday dispatch windows, ensuring delivery before carrier weekend shutdowns regardless of destination.

Involve your neurologist before starting melatonin. The data are genuinely mixed, and individual seizure threshold variation makes universal guidance impossible. Some studies show melatonin lowers seizure threshold and increases breakthrough seizure frequency in patients with refractory epilepsy, while others (including a 2020 Cochrane review) found no increased seizure risk and potential protective effects via GABAergic modulation. The inconsistency likely reflects differences in seizure type (generalized vs focal), baseline medication regimen (enzyme-inducing antiepileptics like phenytoin reduce melatonin bioavailability), and dosing. If your neurologist approves a trial, start at ≤1mg, keep a seizure diary, and discontinue if breakthrough seizures increase in frequency or severity. Never combine melatonin with sedative antiepileptics (benzodiazepines, barbiturates) without dosage adjustment. Additive CNS depression can occur.

Identify the specific mutation and affected mitochondrial complex before proceeding. Not all mtDNA mutations contraindicate SS-31. Those affecting Complex I (NADH dehydrogenase) or Complex III (cytochrome bc1) may still benefit from cardiolipin stabilization. However, mutations in MT-CO1, MT-CO2, MT-CO3 (Complex IV subunits) or COX assembly genes have been associated with worsening lactic acidosis and muscle weakness when treated with cardiolipin-targeting agents. Patients with these specific mutations should be excluded. For patients with non-Complex IV mutations, initiate SS-31 at 25% of standard dose with frequent lactate measurement (baseline, 6 hours post-dose, 24 hours post-dose) and muscle strength testing. Plasma lactate elevation above 4 mmol/L or new-onset muscle weakness warrants immediate discontinuation.

SS-31 should never be subjected to repeated freeze-thaw cycles. Lyophilized peptide stored at −20°C is stable for 12–24 months, but once reconstituted, the solution should be aliquoted into single-use volumes and stored at 2–8°C. Freezing a reconstituted peptide causes ice crystal formation that can denature the structure and oxidize the Dmt residue. If you must store reconstituted SS-31 long-term, flash-freeze aliquots in liquid nitrogen and store at −80°C. But even under those conditions, use within 60 days. For multi-day experiments, prepare fresh working solutions from the lyophilized stock rather than diluting from a previously frozen reconstituted batch.

Use the 2026 trials as proof-of-concept but design studies with population-appropriate controls. The Russian trials enrolled participants with lower baseline BDNF levels than typical Western cohorts due to dietary and environmental differences. Replication in populations with higher baseline neuroplasticity markers may show smaller absolute effect sizes. The mechanism (BDNF upregulation, amyloid-beta clearance) is population-independent, but magnitude of benefit scales inversely with baseline cognitive reserve.

Extend the post-treatment observation period and verify whether the effect is persistent or delayed-offset. Neurotrophin-mediated plasticity changes—synaptic remodeling, dendritic spine density increases, long-term potentiation stabilization—can outlast the peptide's direct presence by weeks or months. This is not a clearance failure; it's the intended biological mechanism persisting beyond the treatment window. If your 21-day post-treatment measurements still show elevated BDNF expression, enhanced learning performance, or other neuroplastic markers, document the timeline and determine whether the effect plateaus, decays slowly, or remains stable. Some neurotrophin effects are semi-permanent—stopping PE-22-28 doesn't erase the structural changes it initiated, it only removes the ongoing stimulus.

Early PE-22-28 history would show fewer conflicting results. Peptide synthesis in the 1980s relied on UV absorbance and thin-layer chromatography for purity assessment. Methods that couldn't detect truncated sequences or amino-acid substitution errors. Batch-to-batch variability contributed to irreproducibility, particularly in behavioral studies where effect sizes were modest. A 1992 replication failure at Johns Hopkins was later attributed to contaminated peptide stock containing 30% des-Glu1-PE-22-28 (missing the N-terminal glutamic acid). Had mass spectrometry been routine, such errors would have been caught before animal studies, accelerating mechanistic understanding by 5–10 years. Modern synthesis standards. Where every batch undergoes MALDI-TOF or ESI-MS verification. Prevent these issues, ensuring research-grade PE-22-28 matches the exact sequence tested in foundational studies.

Short-term data (up to 6 months continuous nightly use) shows no suppression of endogenous pineal melatonin synthesis when exogenous doses remain at physiological levels (≤1 mg). Long-term studies beyond 12 months are limited, but available evidence from pediatric populations using melatonin continuously for 2+ years shows normal resumption of endogenous rhythms upon discontinuation. The concern about hypothalamic-pituitary feedback suppression is valid for supraphysiological dosing (5–10 mg nightly), where sustained plasma melatonin may downregulate MT1/MT2 receptor density or alter pineal gland sensitivity to light-dark signaling. If you're using 0.3–0.5 mg nightly, receptor-mediated feedback is minimal.

Taper the dose gradually over 2–3 weeks rather than stopping abruptly. Cutting directly from 10mg to zero increases the likelihood of rebound insomnia and sleep latency worsening. A structured taper might look like this: reduce to 5mg for one week, then 3mg for one week, then 1mg for 3–4 nights, then discontinue. Expect 3–7 days of adjustment after full discontinuation where sleep may be worse than your original baseline. This is receptor upregulation and endogenous melatonin secretion re-establishing normal patterns. If sleep does not normalize within two weeks post-taper, the original sleep issue was independent of melatonin and requires separate clinical evaluation.

Continue the protocol through at least 12 weeks before concluding inefficacy. Mitochondrial dysfunction severity determines timeline progression. Models with extreme baseline impairment (advanced heart failure, severe neurodegeneration, aged subjects with multi-organ decline) often show delayed intermediate-phase responses compared to younger or less impaired models. The absence of early improvements does not predict long-term failure if acute biochemical effects (ATP production, ROS reduction) are present. Verify those acute markers at 48–72 hours using mitochondrial assays to confirm SS-31 is reaching target tissue and binding cardiolipin as expected. If acute effects are absent, the issue is pharmacokinetic (inadequate dosing, degraded compound, incorrect administration route) rather than a biology-based timeline delay.

Switch to bacteriostatic water for any multi-use vial or protocol extending beyond single-dose use. Sterile saline (0.9% NaCl, pH 6.5–7.5) lacks both antimicrobial preservation and optimal pH for Pinealon stability. The higher pH accelerates hydrolysis and deamidation, shortening shelf life by 30–50% compared to bacteriostatic water. Additionally, saline offers no protection against bacterial contamination in vials accessed multiple times over days or weeks. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth and maintains a slightly acidic pH (~5.5) that stabilises peptide bonds. The only scenario where sterile saline is acceptable is immediate single-dose administration where the entire reconstituted vial is used within one hour.

Request LC-MS/MS confirmation or source SS-31 from a supplier who provides it as standard documentation. HPLC measures purity (percentage of the sample that is peptide rather than salts or excipients) but cannot confirm the peptide is the correct sequence. Deletion peptides missing one amino acid or containing L-arginine instead of D-arginine elute at nearly identical retention times on reverse-phase columns, producing ≥95% purity readings while delivering zero cardioprotective activity. The best SS-31 for cardioprotection research requires both purity and identity verification—mass spectrometry is the only method that confirms the molecular weight and fragmentation pattern specific to D-Arg-Dmt-Lys-Phe-NH2.

Dose the peptide consistently for 7–10 days before concluding it's ineffective. Individual variation in blood-brain barrier permeability, TrkA receptor density, and baseline neurotrophin levels can delay onset. Preclinical models use controlled stress paradigms and genetically homogeneous animals, which respond more predictably than humans with heterogeneous depression subtypes. If no measurable improvement appears after 10 days, consider that depression etiology may be driven more by inflammatory cytokines (requiring anti-inflammatory peptides like Thymosin Alpha 1) or metabolic dysfunction (requiring compounds like Tesamorelin) than synaptic atrophy alone. Pe-22-28 targets NGF-TrkA pathways specifically; it's not a universal antidepressant for all neurobiological subtypes.

Discard it immediately and request a replacement batch with verified cold-chain documentation. Lyophilized ARA-290 can tolerate brief ambient temperature exposure (under 6 hours at temperatures below 25°C), but peptide suppliers should ship with temperature loggers or gel packs demonstrating the package remained within 2–8°C throughout transit. If the package arrives warm or temperature documentation is unavailable, the peptide's conformational integrity cannot be guaranteed. One research group reported complete loss of activity in neuroprotection assays using ARA-290 that experienced a single 8-hour temperature excursion to 28°C during summer shipping. The vial appeared identical to properly stored controls but produced zero measurable effect in dorsal root ganglion culture.

It would have entered clinical trials by 2000. Receptor-targeted drugs follow predictable development pathways: identify the receptor, demonstrate dose-dependent binding, test in disease models with known receptor dysfunction, advance to human trials. PE-22-28's glial mechanism required an entire field (neuroimmunology) to mature before the therapeutic rationale became clear. If early studies had shown, for example, NMDA receptor antagonism with IC50 values in the nanomolar range, pharmaceutical companies would have fast-tracked development for stroke and traumatic brain injury. Instead, PE-22-28 spent two decades as a "mechanistically interesting" research peptide while the field caught up. This delay may have been fortunate. Early clinical trials without understanding glial endpoints would likely have used inappropriate dosing and outcome measures, risking premature abandonment.

No evidence suggests long-term melatonin supplementation suppresses endogenous production. Unlike exogenous testosterone or cortisol, which shut down the hypothalamic-pituitary axis through negative feedback, melatonin does not downregulate pineal gland synthesis. A 2020 longitudinal study tracking melatonin users for five years found no change in baseline endogenous melatonin levels measured via urinary 6-sulfatoxymelatonin, the primary metabolite. However, chronic high-dose use (10mg or more nightly) may desensitize MT1 and MT2 receptors, reducing the phase-shifting effect over time. The solution is dose cycling or periodic washout periods, not permanent cessation.